Access to Information Requests Completed - September 2012

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the month of September 2012

Request #	Summary of Requests	Status of Completed Request	Number of Pages Disclosed
A-2010-01074	All documentation pertaining to project or program funding agreements with - and subsequent deliverables to Health Canada by: Non-Smokers Rights Association (NSRA). (Jan 1, 2006 to Dec 31, 2010).	Disclosed in part	5,915
A-2011-00203	Any memo, letter or email between Health Canada and Providence Health Care (or PHS associate or employee) regarding the SALOME project or the importation of narcotics including heroin. Any memo, letter or email received by Health Canada from the Office of the Prime Minister (PMO) regarding this subject.	Disclosed in part	131
A-2011-00534	AERs for the product Tylenol. Report numbers: 000327012, 000327014, 000327183, 000329273, 000329291, 000331589, 000332332, 000332536, 000332698 and 000332937.	Disclosed in part	55
A-2011-00538	AERs for the product Benylin. Report numbers: 000191447, 000192681, 000193562, 000194107, 000194623, 000198934, 000208340, 000208685, 000209229 and 000210026.	Disclosed in part	69
A-2011-01038	Simian Foamy Virus (SFV): the scientific basis and/or rationale for the July 20, 2001 statement by the Food Directorate: 'If the test result is positive and the individual wishes to notify the Workers Safety Insurance Board (WSIB) or Workers Compensation Board (WCB) or the Commission de la Santé et de la Sécurité au Travail (CSST) or equivalent, the individual will be required to be tested again.	Disclosed in part	6
A-2011-01040	Simian Foamy Virus (SFV): the background information for the Biologics and Genetics Therapies Directorate Directive (D2006-01), issued on May 15, 2006.	Disclosed in part	75
A-2011-01192	All documents as to why the Food Directorate has been unable to keep its 2010 commitment and implement another round of linked Simian Foamy Virus (SFV) testing/retesting. (Mar 1, 2006 to Dec 12, 2012).	Disclosed in part	128
A-2011-01341	AERs. Report numbers: 000377615, 000376235, 000374654, 000375027, 000374210, 000374209 and 000374212.	Disclosed in part	29
A-2011-01680	All correspondence between the US Food and Drug Administration and Health Canada which discuss Sandoz. (Jan 1, 2009 to Mar 30, 2012).	Disclosed in part	33
A-2012-00081	AERs for the product AGGRENOX. Report numbers: 000372537, 000348048 and 000372457.	Disclosed in part	22
A-2012-00203	All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for the product MiniArc Sling System. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	10
A-2012-00247	All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for the product Pelvisoft Acellular Collagen Biomesh. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	19
A-2012-00249	User Manual for Pelvisoft Acellular Collagen Biomesh. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	19
A-2012-00333	Final report for Amounts Paid by the Non-Insured Health Benefits Program to the Eskasoni Pharmacy.	All exempted	0
A-2012-00369	Final report for Amounts Paid by the Non-Insured Health Benefits Program to the St. Joseph Hospital Community Pharmacy.	Disclosed in part	37
A-2012-00370	Final report to the Non-Insured Health Benefits Program for Medical Transportation in Poplar Hill.	Disclosed in part	21
A-2012-00371	Final report for Amounts Paid by the Non-Insured Health Benefits Program to the Fisher Pharmacy.	Disclosed in part	40
A-2012-00372	Final report for Amounts Paid by the Non-Insured Health Benefits Program to Great Glasses.	Disclosed in part	18
A-2012-00373	Final report to the Non-Insured Health Benefits Program for Allegations of Wrongdoing regarding administration of Medical Transportation Benefits Thunder Bay Region.	All exempted	0
A-2012-00374	Final report to the Non-Insured Health Benefits Program for Allegation of wrongdoing against a Mental Health Service Provider - Ontario Region.	Disclosed in part	13
A-2012-00375	Final report to the Non-Insured Health Benefits Program for Woodstock First Nation Health Centre.	Disclosed in part	19
A-2012-00378	AERs. Report numbers: 000370438, 000371012, 000375367, 000376492 and 000379220.	Disclosed in part	15
A-2012-00379	AERs. Report numbers: 000379615, 000380714, 000382830, 000384258 and 000386386.	Disclosed in part	6
A-2012-00387	AERs for the product Avelox. Report numbers: 000391351, 000391354, 000391596, 000391611 and 000392791.	Disclosed in part	106
A-2012-00396	AERs for the product Zevalin. Report number: 000392264.	Disclosed in part	8
A-2012-00406	All documents relating to a meeting of the Scientific Advisory Committee on Non-prescription Drugs held May 10, 2012, pertaining to acne products.	Disclosed in part	137
A-2012-00415	All documents that were created to brief the minister and/or Deputy Minister and/or Associate Deputy Minister regarding methylenedioxypyrovalerone (MDPV), a key ingredient in the drug known as bath salts. (May 25, 2012 to Jun 13, 2012).	Disclosed in part	99
A-2012-00431	All emails, briefing notes and draft reports, originating from the Environmental Public Health Program regarding housing surveys at Attawapiskat First Nation conducted. (Jan 1, 2010 to Sep 4, 2012).	Disclosed in part	145
A-2012-00459	AERs. Report numbers: 000395101, 000394823 and 000395627.	Disclosed in part	16
A-2012-00466	AER for the product Mavik. Report number: 000374234.	Disclosed in part	6
A-2012-00467	AERs for the product Synthroid. Report numbers: 000374531, 000379976 and 000378916.	Disclosed in part	12
A-2012-00469	Information regarding the actual stability (in months) for the product Celebrex 200 mg, DIN 02239942 by Pfizer.	Disclosed in part	13
A-2012-00484	Request a list or schedule of stakeholder meetings about or pertaining to radiofrequency exposure / Radio Frequency fields strengths / electromagnetic fields / specific absorption rates / Safety Code 6 / RSS-102 (Radio Standards Specification) and cell towers / antennae / base stations. (Jan 1, 2009 to Dec 31, 2011).	Disclosed in part	141
A-2012-00485	Request a list or schedule of stakeholder meetings about or pertaining to radiofrequency exposure / Radio Frequency fields strengths / electromagnetic fields / specific absorption rates / Safety Code 6 / RSS-102 (Radio Standards Specification) and cell towers / antennae / base stations. (Jan 1, 2004 to Dec 31, 2008).	Disclosed in part	116
A-2012-00486	Request a list or schedule of stakeholder meetings about or pertaining to radiofrequency exposure / Radio Frequency fields strengths / electromagnetic fields / specific absorption rates / Safety Code 6 / RSS-102 (Radio Standards Specification) and cell towers / antennae / base stations. (Jan 1, 2001 to Dec 31, 2004).	Disclosed in part	55
A-2012-00487	Request a list or schedule of stakeholder meetings about or pertaining to radiofrequency exposure / Radio Frequency fields strengths / electromagnetic fields / specific absorption rates / Safety Code 6 / RSS-102 (Radio Standards Specification) and cell towers / antennae / base stations. (Jan 1, 1997 to Dec 31, 2000).	Disclosed in part	410
A-2012-00489	Documents related to non-compliance to Safety Code 6 in uncontrolled environments, specifically, cell towers / antennae / base stations.	Disclosed in part	7
A-2012-00527	AERs for the product Pantoloc (pantoprazole sodium). Report numbers: 000401437, 000403124 and 000413577.	Disclosed in part	9
A-2012-00529	AERs for the products Alvesco (ciclesonide inhalation aerosol) report number 000420700 and Daxas (roflumilast) report numbers 000400069 and 000418585.	Disclosed in part	7
A-2012-00535	All briefing notes, question period response documents and media response documents (Media Lines) produced dealing with mercury issues at Grassy Narrows, Wabaseemoong and/or Whitedog First Nations. (Jan 1, 2011 to Jul 1, 2012).	Disclosed in part	71
A-2012-00539	AERs for the product Varivax III. Report numbers: 000381180, 000394053, 000394681 and 000396666.	Disclosed in part	9
A-2012-00555	All receipts and itineraries for Minister Aglukkaq's international and domestic travel for enclosed trips (including Minister's Office staff). (Mar 2, 2012 to Jun 28, 2012).	Disclosed in part	275
A-2012-00556	All receipts and itineraries for Minister Aglukkaq's international and domestic travel for enclosed trips (including Minister's Office staff). (Dec 2, 2011 to Mar 1, 2011).	Disclosed in part	255
A-2012-00592	AERs for the product Avelox. Report numbers: 000406761, 000407204, 000409450, 000409899, 000411600 and 000414944.	Disclosed in part	13
A-2012-00604	List of the Medical Device Establishment Licence companies and contact information that have had their fee remission (reduction) denied.	All exempted	0
A-2012-00635	AERs for the product Lovenox (enoxaparin sodium). Report numbers: 000355965, 000358009, 000363607, 000367648, 000371660, 000377129 and 000377557.	Disclosed in part	19
A-2012-00640	AERs for the product Clopixol. Report numbers: 000399224 and 000416075.	Disclosed in part	5
A-2012-00641	AER for the product Cosmegen. Report number: 000421197.	Disclosed in part	4
A-2012-00652	All reports related to the consideration of cumulative effects in assessment of pesticides. (Jan 1, 2007 to Jul 31, 2012).	Disclosed in part	73
A-2012-00658	All the briefing notes on Health Canada offices being moved from downtown Ottawa to Nepean and Kanata. (Jan 1, 2009 to Jun 30, 2012).	No records exist	0
A-2012-00668	All documents that explain how the Natural Health Products Directorate handles health claims related to hair regrowth, improvement in hair condition, or the lessening of hair deterioration.	All disclosed	4
A-2012-00669	All AERs related to Sanofi Pasteur products.	Disclosed in part	53
A-2012-00671	The total cost and annual cost for the four years of work of the Royal Commission on New Reproductive Technologies (also referred to as Baird Commission) established October 25, 1989 and which issued its Final Report to Parliament in November 15, 1993.	No records exist	0
A-2012-00674	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during July 2012.	All disclosed	1
A-2012-00675	List of contracts showing monetary spending, including in the offices of the Minister of Health and the Deputy Minister for the purchase of frames, plants, flowers, electronic devices, photo portraits, furniture, any kind of renovation or repair, the costs of changing burnt-out light bulbs and cleaning the offices of the Minister and Deputy Minister. (Jan 1, 2006 to Jul 31, 2012).	All disclosed	1
A-2012-00691	A list of all legal tobacco products currently sold in Canada as of June 2012.	All disclosed	62
A-2012-00709	All documents relating to any communication between Health Canada and any manufacturer concerning post marketing adverse events related the drug CIPRALEX (Escitalopram), including all generic versions of this drug. (Jan 1, 2005 to Aug 8, 2012).	No records exist	0
A-2012-00710	All documents relating to any communication between Health Canada and any manufacturer concerning post marketing adverse events related the drug PROZAC (fluoxetine hydrochloride), including all generic versions of this drug. (Jan 1, 2005 to Aug 8, 2012).	No records exist	0
A-2012-00711	All documents relating to any communication between Health Canada and any manufacturer concerning post marketing adverse events related the drug ZOLOFT (sertraline hydrochloride), including all generic versions of this drug. (Jan 1, 2005 to Aug 8, 2012).	No records exist	0
A-2012-00760	All documents relating to personal harm and injury caused by the drug CIPRALEX (Escitalopram), including all generic versions of this drug. (Jan 1, 2005 to Aug 8, 2012).	All disclosed	4
A-2012-00763	All periodic or annual safety reports relating to the drug CIPRALEX (Escitalopram), including all generic versions of this drug. (Jan 1, 2005 to Aug 17, 2012).	No records exist	0
A-2012-00764	All periodic or annual safety reports relating to the drug PROZAC (fluoxetine hydrochloride), including all generic versions of this drug. (Jan 1, 2005 to Aug 17, 2012).	No records exist	0
A-2012-00765	All periodic or annual safety reports relating to the drug ZOLOFT (sertraline hydrochloride), including all generic versions of this drug. (Jan 1, 2005 to Aug 17, 2012).	No records exist	0
A-2012-00780	Information pertaining to losses and thefts reports submitted in January 2012 by the province of Ontario for the product 30mg Hydromorph Contin by Purdue Pharma.	Disclosed in part	1
A-2012-00781	Information pertaining to losses and thefts reports submitted in March 2012 by the province of Québec for the product 3mg Hydromorph Contin by Purdue Pharma.	Disclosed in part	1
A-2012-00782	Information pertaining to losses and thefts reports submitted in February 2012 by the province of Alberta for the product Oxycontin 30mg Tablets by Purdue Pharma.	Disclosed in part	1
A-2012-00783	Information pertaining to losses and thefts reports submitted in May 2012 by the province of British Columbia for the product Oxycontin SRT 80mg by Purdue Pharma.	Disclosed in part	1
A-2012-00784	Information pertaining to losses and thefts reports submitted in March 2012 by the province of Nova Scotia for the product Oxycontin SRT 40mg by Purdue Pharma.	Disclosed in part	1
A-2012-00785	Information pertaining to losses and thefts reports submitted in January 2012 by the province of Ontario for the product Oxycontin SRT 40mg by Purdue Pharma.	Disclosed in part	1
A-2012-00786	Information pertaining to losses and thefts reports submitted in January 2012 by the province of Ontario for the product Oxycontin SRT 80mg by Purdue Pharma.	Disclosed in part	1
A-2012-00787	Information pertaining to losses and thefts reports submitted in February 2012 by the province of Ontario for the product Oxycontin SRT 80mg by Purdue Pharma.	Disclosed in part	1
A-2012-00788	All contracts processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of July 2012.	Disclosed in part	8
A-2012-00789	AERs for the product Nplate. Report number: 00363489.	Disclosed in part	1
A-2012-00791	AERs. Report numbers: 000372629 and 000379994.	Disclosed in part	2
A-2012-00795	All contracts processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Task and Solutions Professional Services (TSPS) during the period of May and June 2012.	Disclosed in part	78
A-2012-00797	AERs. Report numbers: 000209389, 000371643, 000201741, 000209391, 000209390, 000168135, 000209486, 000209133, 000221747, 000155248, 000322415 and 000208742.	Disclosed in part	107
A-2012-00808	Documents regarding the Health Canada Wind Turbine Noise and Health Study relating to all conflict of interest disclosures of all the individuals listed in the documents released under file A-2012-00089.	Disclosed in part	54
A-2012-00809	Documents regarding the Health Canada Wind Turbine Noise and Health Study relating to all conflict of interest disclosures of all the individuals listed in the documents released under file A-2012-00492.	Disclosed in part	53
A-2012-00811	Documents regarding the Health Canada Wind Turbine Noise and Health Study relating to the Canadian Council of Academies (or any other organization) for the purpose of providing Health Canada with an independent expert assessment of the existing body of evidence (literature review) on the wind turbine and health issue.	Disclosed in part	18
A-2012-00817	Documents regarding the Health Canada Wind Turbine Noise and Health Study relating to any contract issued to an individual and/or organization for questionnaire development.	Disclosed in part	12
A-2012-00818	Documents regarding all conflict of interest disclosures provided by the 26 members of the team identified in the Health Canada Wind Turbine Noise and Health Study Research Design Working Group Members/Collaborators/Advisor's.	Disclosed in part	54
A-2012-00820	Documents regarding the Health Canada Wind Turbine Noise and Health Study relating to requests for proposals and/or any sole source contract(s) that have been proposed and/or issued and/or awarded.	Disclosed in part	18
A-2012-00832	Information regarding the product Teva-tobramycin (tobramycin), DIN 02389622 by Teva Canada Limited.	No records exist	0
A-2012-00837	All draft copies of the 2012 Patented Medicine Prices Review Board report to Parliament, plus any e-mails regarding the report or its draft version sent by or to the Minister of Health, Paul Glover, Mary Catherine, Lindberg, or Michelle Boudreau.	No records exist	0
A-2012-00841	All documents mentioning the Canadian Association of Provincial Cancer Agencies. (Sep 1, 2011 to Aug 22, 2012).	No records exist	0
A-2012-00843	All documents mentioning the Canadian Cancer Action Network. (Sep 1, 2011 to Aug 22, 2012).	No records exist	0
A-2012-00846	Product Monograph for the product AMOXICILLIN, DIN 02237154 by ABBOTT LABRATORIES.	No records exist	0
A-2012-00851	AERs for the product Avelox. Report numbers: 000416995, 000418409, 000418885, 000419494, 000419500, 000419848, 000420300, 000420621, 000420806, 000421756 and 000423682.	Disclosed in part	15
A-2012-00852	AERs for the product Cipro. Report numbers: 000418483, 000418746, 000419983, 000421343, 000422699 and 000423149.	Disclosed in part	8
A-2012-00853	AER for the product Gadovist. Report number: 000423926.	Disclosed in part	2
A-2012-00854	AER for the product Levitra. Report number: 000417811.	Disclosed in part	1
A-2012-00856	AER for the product Yasmin. Report number: 000415113.	Disclosed in part	1
A-2012-00857	All documents related to a meeting between NorTerra Inc and Leona Algukkaq held on July 11 2009.	No records exist	0
A-2012-00859	Documents regarding an Environics survey, commissioned by Health Canada, referred to in the August 7, 2012 Ottawa Citizen article "Warnings don't lead smokers to quit; Only 1 in 3 smoke fewer cigarettes after reading messages, survey finds".	All disclosed	1
A-2012-00861	A listing of the Access to Information requests submitted to Health Canada. (Jul 1, 2012 to Jul 31, 2012).	Disclosed in part	11
A-2012-00866	Information regarding the Natural Healh Product CORECTINby Constab International Inc.	All exempted	0
A-2012-00932	All documents between First Nations and Inuit Health Branch eHealth Solutions Unit and the Indian Residential Schools Adjudication Secretariat Regional Office regarding the Indian Residential Schools Independent Assessment Process (IAP) application form and guide book and the data entry/input, storage, protection, privacy, sharing of IAP form data.	No records exist	0